Skip to main content
. 2022 May;14(5):1588–1597. doi: 10.21037/jtd-22-463

Figure 2.

Figure 2

Probabilistic sensitivity analysis of the empagliflozin group compared to the control group for different populations: (A) total population; (B) those with diabetes; (C) those without diabetes. WTP, willingness to pay; QALYs, quality-adjusted life years.